Recent Updates — ANL

Adlai Nortye Group Ltd. entered into clinical trial collaboration and supply agreements with Eli Lilly and Company and Merck KGaA, Darmstadt, Germany to evaluate the combination of its investigational ADC AN4035 and cetuximab in an ongoing global Phase I trial for CEACAM5-enriched RAS-addicted solid tumors. Under the terms, Lilly will supply cetuximab at no cost for U.S. sites, while Merck KGaA will provide it for sites in Australia and China. The company operates as a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies.

Adlai Nortye Group Ltd. appointed Christopher Liu, PharmD, as Head of Investor Relations and Public Relations on September 30, 2026. Dr. Liu joins the company with nearly a decade of equity research experience in biotechnology and oncology, most recently serving as Managing Director at Lucid Capital Markets. This appointment aims to strengthen engagement with the global investment community and enhance external communications regarding the company's clinical-stage pipeline. Adlai Nortye Group Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies.

On September 8, 2026, Adlai Nortye Group Ltd. announced the dosing of its first patient in Australia for AN4035, a first-in-class antibody-drug conjugate (ADC) targeting CEACAM5 armed with a pan-RAS(ON) inhibitor payload. This event initiates the global Phase I clinical trial for patients with CEACAM5-enriched RAS-addicted solid tumors. The company also received a 'Study-May-Proceed' letter from the U.S. FDA regarding its investigational new drug application, clearing the path to expand the trial into the United States. Management aims to report full Phase Ia data in the second half of 2027 and is concurrently filing an IND with China's NMPA. Adlai Nortye Group Ltd. operates as a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies.